• Alí Duarte-García, Ying Ying Leung, Laura C Coates, Dorcas Beaton, Robin Christensen, Ethan T Craig, Maarten de Wit, Lihi Eder, Lara Fallon, Oliver FitzGerald, Dafna D Gladman, Niti Goel, Richard Holland, Chris Lindsay, Lara Maxwell, Philip Mease, Ana Maria Orbai, Beverley Shea, Vibeke Strand, Douglas J Veale, William Tillett, and Alexis Ogdie.
• From the Division of Rheumatology, Department of Medicine, and the Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota; Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Rheumatology, Duke University School of Medicine, Durham, North Carolina; Kezar Life Sciences, South San Francisco; Amgen Inc., Thousand Oaks, California; Swedish-Providence-St. John's Health Systems and University of Washington, Seattle, Washington; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore; University of Leeds, Leeds; University of Oxford, Oxford; Royal National Hospital for Rheumatic Diseases; University of Bath, Bath, UK; Musculoskeletal Health and Outcomes Research, St. Michael's Hospital; Institute for Work and Health; Department of Occupational Science and Occupational Therapy, Rehabilitation Sciences Institute and the Institute for Health Policy Management and Evaluation, University of Toronto; Department of Medicine, University of Toronto, Women's College Hospital; Department of Medicine, University of Toronto, Toronto Western Hospital, Toronto; Cochrane Musculoskeletal Group, Ottawa Hospital Research Institute, Centre for Practice-Changing Research; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario; Pfizer Inc., Montreal, Quebec, Canada; Musculoskeletal Statistics Unit: The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen; Department of Rheumatology, Odense University Hospital, Odense, Denmark; Department of Medical Humanities, Patient Research Partner, Amsterdam University Medical Centre, Amsterdam, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital; Conway Institute for Biomolecular Research, University College Dublin, Ireland; Royal Prince Alfred Hospital Medical Centre, Sydney, Australia.
• J Rheumatol. 2019 Aug 1; 46 (8): 996-1005.

ObjectiveThe Psoriatic Arthritis (PsA) Core Domain Set for randomized controlled trials and longitudinal observational studies has recently been updated. The joint counts are central to the measurement of the peripheral arthritis component of the musculoskeletal (MSK) disease activity domain. We report the Outcome Measures in Rheumatology (OMERACT) 2018 meeting's approaches to seek endorsement of the 66/68 swollen and tender joint count (SJC66/TJC68) for inclusion in the PsA Core Outcome Measurement Set (COS).MethodsUsing the OMERACT Filter 2.1 Instrument Selection Process, the SJC66/TJC68 was assessed for (1) domain match, (2) feasibility, (3) numerical sense (construct validity), and (4) discrimination (test retest reliability, longitudinal construct validity, sensitivity in clinical trials, and thresholds of meaning). A protocol was designed to assess the measurement properties of the SJC66/TJC68 joint count. The results were summarized in a Summary of Measurement Properties table developed by OMERACT. OMERACT members discussed and voted on whether the strength of the evidence supported that the SJC66/TJC68 had passed the OMERACT Filter as an outcome measurement instrument for the PsA COS.ResultsOMERACT delegates endorsed the use of the SJC66/TJC68 for the measurement of the peripheral arthritis component of the MSK disease activity domain. Among patient research partners, 100% voted for a "green" endorsement, whereas among the group of other stakeholders, 88% voted for a "green" endorsement.ConclusionThe SJC66/TJC68 is the first fully endorsed outcome measurement instrument using the OMERACT Filter 2.1 and the first instrument fully endorsed within the PsA COS.

20 keywords...

hide…